Study on Amlodipine for Treating Reversible Cerebral Vasoconstriction Syndrome in Patients Without Brain Lesions or Hemorrhage

This clinical trial is focused on studying a condition known as Reversible Cerebral Vasoconstriction Syndrome (RCVS). This condition involves the temporary narrowing of blood vessels in the brain, which can lead to severe headaches. The study will explore the use of a medication called Amlodipine, which is a type of drug known as a calcium channel blocker. This medication is commonly used to treat high blood pressure by helping to relax blood vessels.

The purpose of the study is to determine if adding Amlodipine to the standard care for patients with RCVS can help reduce the frequency of recurring headache attacks. Participants in the study will be randomly assigned to receive either Amlodipine or a placebo, and neither the participants nor the researchers will know which treatment is being given. This is known as a double-blind study. The study will last for a period of up to 12 weeks, during which participants will take the medication orally in the form of a tablet.

Throughout the study, the main focus will be on observing how often headaches occur. Additionally, researchers will monitor for any changes in the brain's blood vessels using imaging techniques like CT (computed tomography) or MRI (magnetic resonance imaging). The study will also look for any potential complications, such as strokes or other issues, and assess the intensity of headache attacks. The goal is to gather information that could lead to better treatment options for those affected by RCVS.